Etoposide induces chromosomal abnormalities in mouse spermatocytes and stem cell spermatogonia
Authors:
- Francesco MarchettiFMFrancesco Marchetti
- Jack B. BishopJBJack B. Bishop
- Andrew J. WyrobekAWAndrew J. Wyrobek
Open Access
- 25 November 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (4) , 888-895
Abstract
BACKGROUND: Etoposide (ET) is a chemotherapeutic agent widely used in the treatment of leukaemia, lymphomas and many solid tumours such as testicular and ovarian cancers, all of which are common in patients of reproductive age. The purpose of the study was to characterize the long-term effects of ET on male germ cells using sperm fluorescence in situ hybridization (FISH) analyses. METHODS: Chromosomal aberrations (partial duplications and deletions) and whole chromosomal aneuploidies were detected in sperm of mice treated with a clinical dose of ET. Semen samples were collected at 25 and 49 days after dosing to investigate the effects of ET on meiotic pachytene cells and spermatogonial stem-cells, respectively. RESULTS: ET treatment resulted in major increases in the frequencies of sperm-carrying chromosomal aberrations in both meiotic pachytene (27- to 578-fold) and spermatogonial stem-cells (8- to 16-fold), but aneuploid sperm were induced only after treatment of meiotic cells (27-fold) with no persistent effects in stem cells. CONCLUSION: These results show that ET may have long-lasting effects on the frequencies of sperm with structural aberrations. This has important implications for cancer patients undergoing chemotherapy with ET because they may remain at higher risk for abnormal reproductive outcomes long after the end of chemotherapy.Keywords
This publication has 45 references indexed in Scilit:
- Analysis of expression and function of topoisomerase I and II during meiosis in male miceMolecular Reproduction and Development, 1997
- Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrationsMutagenesis, 1997
- Topoisomerase II inhibition in mitosis produces numerical and structural chromosomal aberrations in human fibroblastsCytogenetic and Genome Research, 1997
- Mutagenicity of anticancer drugs that inhibit topoisomerase enzymesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996
- Numerical and structural chromosome aberrations induced by etoposide (VP16) during oocyte maturation of mice: transmission to one-cell zygotes and damage to dictyate oocytesMutagenesis, 1996
- Resolving the role of topoisomerase II in chromatin structure and functionTrends in Cell Biology, 1995
- Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cellsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1995
- Preferential pericentric lesions and aneuploidy induced in mouse oocytes by the topoisomerase II inhibitor etoposideTeratogenesis, Carcinogenesis, and Mutagenesis, 1994
- DNA topoisomerase dysfunction: A new goal for antitumor chemotherapyBioEssays, 1990
- Segregation of recombined chromosomes in meiosis I requires DNA topoisomerase IICell, 1990